Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

inesses, research capabilities and geographic markets. The OBS acquisition has provided greater diversity, new treatment areas, global leadership in animal health and a deeper R&D pipeline.

"When we began this journey in 2003, Schering-Plough had five new molecular entity projects or novel combination products in Phase III clinical trials or in registration," said Hassan. "Now, we have more than doubled our number of compounds in Phase III or registration. Our late-stage pipeline is one of the strongest in our peer group."

In early April, Schering-Plough launched a new Productivity Transformation Program (PTP) to address the increasing pressures on the pharmaceutical industry, especially new pressures in the United States, and the confusion in the U.S. cholesterol management market that is affecting ZETIA and VYTORIN. "We are taking decisive actions to reduce and avoid costs and to accelerate our productivity initiatives," said Hassan. "We will continue to take tough actions to sustain long-term, high performance."

The company has targeted annual savings from PTP of $1.5 billion, which represents approximately 10 percent of the combined company's (Schering-Plough/OBS) full-year 2007 estimated cost base. This target includes the previously announced OBS integration synergy goal of $500 million and anticipates a 10 percent reduction in the global work force, or about 5,500 jobs.

"We will be disciplined and rigorous in how we achieve these savings," said Hassan, "and we will execute this program with care and prudence. Savings and productivity improvements will be realized throughout our company and around the world. But we don't expect the same level of cost reduction to be applied across the board. We will continue to focus on our basic strategy: Grow the top line; grow the R&D pipeline; reduce costs while investing wisely."

OBS Integration

The company reviewed progress in the integration of OBS since the transaction closed i
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2010)... Stock Exchange Symbol: MS , ... , , ... ... EDMONTON , March 16 ... ...
(Date:3/16/2010)... PharmAthene, Inc. (Amex: PIP ) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results ... ... , ... ... ...
(Date:3/16/2010)... March 16 The Gynecologic Cancer Foundation (GCF) and the Claudia ... as the first recipient of the $50,000 GCF/Claudia Cohen Prize for Outstanding ... (SGO) 41st Annual Meeting on Women,s Cancer, meeting in San Francisco ... ... ...
(Date:3/16/2010)... (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice ... New Drug Application ("ANDA") for a generic version of Shire,s 1,mg, 2mg, ... ... ... , ...
Breaking Biology Technology:BioMS Medical Announces 2009 Year End Results 2BioMS Medical Announces 2009 Year End Results 3BioMS Medical Announces 2009 Year End Results 4BioMS Medical Announces 2009 Year End Results 5BioMS Medical Announces 2009 Year End Results 6BioMS Medical Announces 2009 Year End Results 7BioMS Medical Announces 2009 Year End Results 8BioMS Medical Announces 2009 Year End Results 9BioMS Medical Announces 2009 Year End Results 10PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 2PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 2Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 4Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 5Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4
... 7, 2008,at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 ... CTIC ) (MTA: CTIC) management,team will host ... 2008,third quarter achievements and financial results., ... 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific ...
... Nov. 5 In a survey of 100 ... Merck,was perceived as standing out above other companies ... having the best overall image,in infectious disease. GlaxoSmithKline, ... in overall image among the specialists., The ...
... As biopharmaceutical,companies continue to bring new ... strategy and execution from development through launch, ... and little else. In,a continuing effort to ... conducted by Best Practices, LLC reviewing launch ...
Other Biology Technology:According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists 2New Study Provides Key Findings for Biopharma Product Launch Evaluation 2
(Date:3/18/2010)... can live for twenty years, fertilizing millions of eggs ... activity. , Danish researchers who have studied ants ... 1992 discovered that in both ant and bee species ... fluid favors the survival of its own sperm over ... stored, leafcutter ant queens neutralize male-male sperm competition with ...
(Date:3/18/2010)... available in Spanish . , Feeding ... as part of their regular diet makes them ... a study by Agricultural Research Service (ARS) scientists ... and overall behavioral activity among young female pigs ... acquired through diet, is the precursor for the ...
(Date:3/18/2010)... Biotech, Inc., ( www.genwaybio.com ) the US-based diagnostic company ... is expanding this cancer testing program internationally. An ... YouTM Cancer Assessment in Greece starting in April. ... as well. GenWay currently offers this test in ... Sergey Sikora, Vice President of Business Development, said, "The ...
Breaking Biology News(10 mins):Females shut down male-male sperm competition in leafcutter ants 2Tryptophan-enriched diet reduces pig aggression 2Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 1Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 2Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 1Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 1Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 3
... story has both UCLA and a team of enterprising UCLA ... care. , In 1996, a unique collaboration of ... biotechnology company Agensys Inc. and the company now stands ... Inc., making it one of the largest Los Angeles-based private ...
... waste resulting from the nations nuclear weapons program lie ... Hanford. Beneath this desert landscape about two million ... of chemicals are captured within the stratified vadose zone ... These paths create uncertainties about where the contaminants ...
... CHICAGOMore than 30 years in the making, Birds of ... plates, 1,700 species distribution maps, also in color, and ... landmark publication, Tom Schulenberg, PhD, and Douglas Stotz, PhD, ... Environmental and Conservation Program. Therefore the Museum will host ...
Other Biology News:Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 2Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 3Where does stored nuclear waste go? 2Lavishly illustrated guide to Peru's birds describes 1,800 species 2
... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...
...
...
...
Biology Products: